Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The c-Met receptor, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that plays a crucial role in cell proliferation, survival, and motility. It is activated by its ligand hepatocyte growth factor (HGF), leading to downstream signaling cascades such as MAPK/RAS, PI3K/AKT, and STAT pathways. Dysregulation of c-Met signaling is implicated in various cancers, making it an important therapeutic target. Aberrant activation can occur through genetic mutations, gene amplification, protein overexpression, or increased HGF expression.
c-Met inhibitors block the kinase activity of the receptor, preventing downstream signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on c-Met receptor (MET).